Barbara Burtness, professor of medicine (medical oncology), has been named chief translational research officer for Yale Cancer Center and Smilow Cancer Hospital, and associate cancer center director for translational research for Yale Cancer Center.
Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.
